Xolair Pediatric Indication Is Too Broad, Clinical Effect Too Small For FDA Committee
This article was originally published in The Pink Sheet Daily
Executive Summary
Seven-seven split on first key vote on "clinically meaningful beneficial effect" of omalizumab in children above age six sends decision on BLA back to FDA - not a friendly venue for sponsors Genentech and Novartis. The three FDA staffs involved in the BLA review (pediatric, pulmonary and drug safety) are united in opposition to current application.
You may also be interested in...
Xolair Pediatric (Ages 6-11) BLA Extension Must Overcome "Relatively Modest" Efficacy
FDA briefing materials for Nov. 18 advisory committee meeting note reductions in asthma exacerbations but few clinically meaningful benefits on secondary efficacy measures.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.